ProCE Banner Activity

OlympiA: 10-Yr Follow-up With Adjuvant Olaparib in Patients With gBRCA1/2-Mutated HER2-Negative Early Breast Cancer

Conference Coverage
Slideset

Long-term efficacy and safety results from the randomized phase III OlympiA study continues to demonstrate that adjuvant olaparib improved invasive and distant disease–free survival, and overall survival vs placebo among patients with high-risk, gBRCA1/2 mutation–positive, HER2-negative early breast cancer.

Released: December 18, 2024

Expiration: June 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation